[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
April 2016

Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations

Author Affiliations
  • 1Center for Surgery and Public Health, Brigham and Women’s Hospital, Boston, Massachusetts
  • 2Division of Urological Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
JAMA Intern Med. 2016;176(4):546-547. doi:10.1001/jamainternmed.2015.7901

The use of prostate-specific antigen (PSA) testing for early detection of prostate cancer remains controversial.1 In October 2011, the US Preventive Services Task Force (USPSTF) issued a recommendation against PSA screening for all men.2 This change was associated with a decline in rates of PSA testing among men aged 50 to 74 years and a decline in cases of incident prostate cancer.3,4 Given the evidence for heterogeneity in screening practices,5 we sought to compare the use of PSA testing among urologists vs primary care physicians (PCPs) before and after the latest USPSTF guidelines, hypothesizing that the adoption of these recommendations would vary according to physician specialty.

First Page Preview View Large
First page PDF preview
First page PDF preview